Loading...
•
Dec 31, 2019
10X Genomics Q4 2019 Earnings Report
10x Genomics reported a revenue increase driven by instrument sales and gross margin improvement due to lower royalties. Operating expenses decreased, leading to a reduced operating loss and net loss compared to the previous year.
Key Takeaways
10x Genomics reported a 49% increase in revenue for Q4 2019, reaching $75.3 million. The company's gross margin improved to 78%, and operating expenses decreased significantly. As a result, the operating loss and net loss were substantially reduced compared to the same period in the prior year.
Revenue increased by 49% to $75.3 million compared to Q4 2018.
Gross margin improved to 78% due to lower accrued royalties.
Operating expenses decreased by 40% due to lower R&D and contingent liabilities.
Operating loss decreased from $75.0 million to $8.1 million year-over-year.
Forward Guidance
10x Genomics expects full year 2020 revenue to be in the range of $350 million to $360 million, representing 42% to 46% growth over full year 2019 revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...